Emory University

Abbott Laboratories Corporation

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Rush University Medical Center

Arshed A Quyyumi

Jochen Reiser

Agim Beshiri

Toren Finkel

Salim Hayek

Jonathan M Hill

Methods and compositions for treating acute kidney injury in a subject are provided. The methods include measuring or having measured a level of soluble urokinase plasminogen activator receptor (suPAR) in a biological sample from the subject, determining or having determined the level of suPAR in the sample compared to a control suPAR level, and administering a therapeutically effective amount of an agent that antagonizes soluble urokinase plasminogen activator receptor (suPAR) to the subject having an elevated level of suPAR relative to the control suPAR level.

suPAR and prediction and treatment of acute kidney injury

Provided herein are methods for predicting or determining whether a subject with coronary artery disease is likely to experience or develop a major adverse cardiovascular event (MACE) based on determining cardiac troponin (cTnI) levels in a human at rest and during or after exercise.

Methods for predicting major adverse cardiovascular events in subjects with coronary artery disease

A method for diagnosing decreased vascular function is disclosed. The method includes assaying the number of endothelial progenitor cells. A method for detecting increased cardiovascular risk is also disclosed, as is a method for diagnosing atherosclerosis. In one example, the methods include assaying the number of endothelial progenitor cells. A method for treating a subject with decreased vascular function is disclosed. The method includes administering a therapeutically effective amount of endothelial progenitor cells to the subject. In one embodiment, the subject has atherosclerosis.

Method for diagnosis and treatment of vascular disease

Growing community of inventors

Atlanta, GA, United States of America

Arshed A Quyyumi